These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21796820)

  • 41. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 42. Deal watch: M&A activity in 2009.
    Walker J
    Nat Rev Drug Discov; 2010 Feb; 9(2):95. PubMed ID: 20118956
    [No Abstract]   [Full Text] [Related]  

  • 43. Finnish biotechnology--built on solid foundations.
    Lähteenmäki R
    Nature; 2002 Dec; 420(6916 Suppl):A34-5, A37, A39. PubMed ID: 12501125
    [No Abstract]   [Full Text] [Related]  

  • 44. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 45. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 46. Pfizer swallows Wyeth, validates niche buster.
    Sheridan C
    Nat Biotechnol; 2009 Mar; 27(3):218-9. PubMed ID: 19270661
    [No Abstract]   [Full Text] [Related]  

  • 47. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

  • 48. Prescription for an ailing pharmaceutical industry.
    Demain AL
    Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
    [No Abstract]   [Full Text] [Related]  

  • 49. Back on target.
    Webb S
    Nat Biotechnol; 2013 Mar; 31(3):191-3. PubMed ID: 23471062
    [No Abstract]   [Full Text] [Related]  

  • 50. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 51. Analysts: Isis-Lilly deal validates antisense.
    Niiler E
    Nat Biotechnol; 2001 Oct; 19(10):898-9. PubMed ID: 11581643
    [No Abstract]   [Full Text] [Related]  

  • 52. Big biotech buys iconic genetics firm.
    Baker M
    Nature; 2012 Dec; 492(7429):321. PubMed ID: 23257857
    [No Abstract]   [Full Text] [Related]  

  • 53. Biotech giant helps itself without swallowing Galapagos whole.
    Senior M
    Nat Biotechnol; 2019 Oct; 37(10):1104-1105. PubMed ID: 31578499
    [No Abstract]   [Full Text] [Related]  

  • 54. India: 50 years after independence.
    Miller DD; Nayak AR
    Nat Biotechnol; 1997 Aug; 15(8):727-9. PubMed ID: 9255782
    [No Abstract]   [Full Text] [Related]  

  • 55. Best of both worlds.
    Smaglik P
    Nature; 2003 Dec; 426(6967):706-7. PubMed ID: 14668875
    [No Abstract]   [Full Text] [Related]  

  • 56. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
    Micklus A; Muntner S
    Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
    [No Abstract]   [Full Text] [Related]  

  • 57. Biotech industry faces new bottleneck.
    Garber K
    Nat Biotechnol; 2001 Mar; 19(3):184-5. PubMed ID: 11231516
    [No Abstract]   [Full Text] [Related]  

  • 58. Mike Varney.
    Varney M; Mullard A
    Nat Rev Drug Discov; 2015 Mar; 14(3):158-9. PubMed ID: 25677359
    [No Abstract]   [Full Text] [Related]  

  • 59. Where have all the investors gone?: the case for consolidation.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1998 May; 16 Suppl():63. PubMed ID: 9591277
    [No Abstract]   [Full Text] [Related]  

  • 60. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.